Teriparatide Induced Delayed Persistent Hypercalcemia | Zendy

Nirosshan Thiruchelvam | Zendy; Jaskirat Randhawa | Zendy; Happy Sadiek | Zendy; Gaurav Kistangari | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Teriparatide Induced Delayed Persistent Hypercalcemia

Author(s) -

Nirosshan Thiruchelvam,

Jaskirat Randhawa,

Happy Sadiek,

Gaurav Kistangari

Publication year - 2014

Publication title -

case reports in endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.26

H-Index - 6

eISSN - 2090-6501

pISSN - 2090-651X

DOI - 10.1155/2014/802473

Subject(s) - teriparatide , medicine , osteoporosis , complication , anabolism , endocrinology , bone mineral

Teriparatide, a recombinant PTH, is an anabolic treatment for osteoporosis that increases bone density. Transient hypercalcemia is a reported side effect of teriparatide that is seen few hours following administration of teriparatide and resolves usually within 16 hours of drug administration. Persistent hypercalcemia, although not observed in clinical trials, is rarely reported. The current case describes a rare complication of teriparatide induced delayed persistent hypercalcemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research